Clinical landscape of LAG-3-targeted therapy

Simple item page
dc.contributor.authorChocarro de Erauso, Luisa
dc.contributor.authorBlanco, Ester
dc.contributor.authorArasanz Esteban, Hugo
dc.contributor.authorFernández Rubio, Leticia
dc.contributor.authorBocanegra Gondán, Ana Isabel
dc.contributor.authorEchaide Górriz, Míriam
dc.contributor.authorGarnica, Maider
dc.contributor.authorRamos, Pablo
dc.contributor.authorFernández Hinojal, Gonzalo
dc.contributor.authorVera García, Ruth
dc.contributor.authorKochan, Grazyna
dc.contributor.authorEscors Murugarren, David
dc.contributor.departmentCiencias de la Saludes_ES
dc.contributor.departmentOsasun Zientziakeu
dc.contributor.funderGobierno de Navarra / Nafarroako Gobernuaes
dc.date.accessioned2023-02-23T08:19:58Z
dc.date.available2023-02-23T08:19:58Z
dc.date.issued2022
dc.date.updated2023-02-23T07:54:44Z
dc.description.abstractLymphocyte-activated gene 3 (LAG-3) is a cell surface inhibitory receptor and a key regulator of immune homeostasis with multiple biological activities related to T-cell functions. LAG-3 is considered a next-generation immune checkpoint of clinical importance, right next to programmed cell death protein 1 (PD-1) and cytotoxic T-cell lymphocyte antigen-4 (CTLA-4). Indeed, it is the third inhibitory receptor to be exploited in human anticancer immunotherapies. Several LAG-3-antagonistic immunotherapies are being evaluated at various stages of preclinical and clinical development. In addition, combination therapies blocking LAG-3 together with other immune checkpoints are also being evaluated at preclinical and clinical levels. Indeed, the co-blockade of LAG-3 with PD-1 is demonstrating encouraging results. A new generation of bispecific PD-1/LAG-3-blocking agents have also shown strong capacities to specifically target PD-1+ LAG-3+ highly dysfunctional T cells and enhance their proliferation and effector activities. Here we identify and classify preclinical and clinical trials conducted involving LAG-3 as a target through an extensive bibliographic research. The current understanding of LAG-3 clinical applications is summarized, and most of the publically available data up to date regarding LAG-3-targeted therapy preclinical and clinical research and development are reviewed and discussed.en
dc.description.sponsorshipThe OncoImmunology group is funded by the Spanish Association against Cancer ( AECC ) [grant number PROYE16001ESCO ]; Instituto de Salud Carlos III (ISCIII)-FEDER project grants [grant numbers FIS PI17/02119, FIS PI20/00010, COV20/00000, TRANSPOCART ICI19/00069]; a Biomedicine Project grant from the Department of Health of the Government of Navarre [grant number BMED 050-2019 ]; strategic projects from the Department of Industry, Government of Navarre (AGATA, Ref. 0011-1411-2020-000013; LINTERNA, Ref. 0011-1411-2020-000033; DESCARTHES, 0011-1411-2019-000058); European Project Horizon 2020 Improved Vaccination for Older Adults (ISOLDA; ID: 848166); Crescendo Biologics Ltd. supported the OncoImmunology group for the development and testing of PD-1 and LAG-3 bispecifics.en
dc.format.mimetypeapplication/pdfen
dc.format.mimetypeapplication/zipen
dc.identifier.citationChocarro, L., Blanco, E., Arasanz, H., Fernández-Rubio, L., Bocanegra, A., Echaide, M., Garnica, M., Ramos, P., Fernández-Hinojal, G., Vera, R., Kochan, G., & Escors, D. (2022). Clinical landscape of LAG-3-targeted therapy. Immuno-Oncology and Technology, 14, 100079. https://doi.org/10.1016/j.iotech.2022.100079en
dc.identifier.doi10.1016/j.iotech.2022.100079
dc.identifier.issn2590-0188
dc.identifier.urihttps://academica-e.unavarra.es/handle/2454/44807
dc.language.isoengen
dc.publisherElsevieren
dc.relation.ispartofImmuno-Oncology and Technology 14(100079), 1-9en
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI17%2F02119/ES/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI20%2F00010/ES/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/ICI19%2F00069/ES/
dc.relation.projectIDinfo:eu-repo/grantAgreement/European Commission/Horizon 2020 Framework Programme/848166/
dc.relation.publisherversionhttps://doi.org/10.1016/j.iotech.2022.100079
dc.rights© 2022 The Author(s). This is an open access article under the CC BY license.en
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectCancer treatmenten
dc.subjectImmune checkpointen
dc.subjectImmunotherapyen
dc.subjectLAG-3en
dc.subjectTargeted therapyen
dc.titleClinical landscape of LAG-3-targeted therapyen
dc.typeinfo:eu-repo/semantics/article
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dspace.entity.typePublication
relation.isAuthorOfPublicationfe5c362e-3c0c-4edb-aa2e-0de27c815ad2
relation.isAuthorOfPublication.latestForDiscoveryfe5c362e-3c0c-4edb-aa2e-0de27c815ad2

Files

Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
Chocarro_ClinicalLandscape.pdf
Size:
412.46 KB
Format:
Adobe Portable Document Format
Download
No Thumbnail Available
Name:
Chocarro_ClinicalLandscape_MatCompl.zip
Size:
55.95 KB
Format:
ZIP
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.78 KB
Format:
Item-specific license agreed to upon submission
Description:
Download

Collections

Artículos de revista DCS - OZS Aldizkari artikuluak
Artículos de revista - Aldizkari artikuluak